Refractory right heart failure is common during the postoperative period after left ventricular assist device implantation. Oral phosphodiesterase-5 inhibitors are oft initiated in order to facilitate weaning from the intravenous inotropic substances. following this period many patients continue to receive the same medication in the long term, despite missing data on its therapeutic effect on right ventricular function.We hypothesise that beyond the acute postoperative period no additional benefit from the phosphodiesterase-5 inhibitors exists. The aim of the study is a detailed clinical and echocardiographic assessment of the right ventricular function after discontinuation of the medication in patients pretreated for at least one month after receiving left ventricular assist device.
The study aims to assess clinical and echocardiographic measures of right ventricular function before and after discontinuation of the oral phosphodiesterase-5 inhibitor in patients on left ventricular device support. At baseline and after discontinuation of the medication patients will receive a clinical examination and New York Heart Association Classification, echocardiographic assessment of right ventricular function, cardiopulmonary exercise testing, 6 minute walking test and assessment of quality of life. The primary outcome is the change of the quantitative echocardiographic parameters of right ventricular function at follow-up. Secondarily, we aim to assess the change in cardiopulmonary exercise capacity, the 6-minute walking distance and quality of life.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
32
discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
University Hospital Essen
Essen, North Rhine-Westphalia, Germany
Change from baseline in right ventricular global longitudinal strain
Change in right ventricular function from baseline as assessed by global longitudinal strain of the right ventricle on transthoracic echocardiography
Time frame: 4 weeks after discontinuation of phosphodiesterase-5 inhibitors
Change from baseline in peak oxygen uptake rate
Change from baseline in functional status as estimated by peak oxygen uptake rate in cardiopulmonary exercise testing
Time frame: 4 weeks after discontinuation of phosphodiesterase-5 inhibitors
Change from baseline in 6-minute walking distance
Change from baseline in walking distance assessed by 6-minute walking test
Time frame: 4 weeks after discontinuation of phosphodiesterase-5 inhibitors
Change from baseline in the total score of quality of life calculated with the Kansas City Cardiomyopathy Questionnaire
Change from baseline in the total score calculated with the Kansas City Cardiomyopathy Questionnaire (range between 0 and 100, higher value indicates worse status of quality of life)
Time frame: 4 weeks after discontinuation of phosphodiesterase-5 inhibitors
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.